Support lifting restrictions on Medicare negotiating drug costs with pharmaceutical companies.

Becca Balint · Vermont · Democratic

policy impact 4.00 specificity 1.00 extraction confidence 97%

Occurrences

Do you support lifting the restrictions for Medicare to negotiate drug costs with pharmaceutical companies? Yes, I support.

Supports giving Medicare broader drug price negotiation authority.

2022_aft-aft_vermont_candidate_questionnaire-beccabalint.pdf
primary · other · model gpt-5.4-mini

Evidence

The Supreme Court rejected pharmaceutical companies' appeals, leaving Medicare's drug-price negotiation program in place and allowing the negotiations to continue.

Confirms the federal Medicare negotiation authority remains intact after a 2026 court challenge.

delivered same_term

Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations
secondary · model gpt-5.4-mini · confidence 88%

Balint's office says she held a webinar with Medicare Advantage experts on October 30, 2025 to discuss changes coming to Medicare Advantage in 2026.

Shows Balint is actively engaged on Medicare policy in her current House term, though not specifically on drug-price negotiation.

partial same_term A for effort

Resources: Medicare | U.S. Representative Becca Balint
secondary · model gpt-5.4-mini · confidence 69%

Balint joined colleagues to reintroduce the PrEP Access and Coverage Act, legislation to expand access to lifesaving HIV prevention medications.

Concrete legislative action on medication access in Balint's current term, consistent with a broader pro-affordability health-care posture.

partial same_term A for effort

Health Care | U.S. Representative Becca Balint
secondary · model gpt-5.4-mini · confidence 62%

Assessments

partial same_term

The promised policy objective was substantially achieved at the federal level, because Medicare’s drug-price negotiation authority was created by the Inflation Reduction Act signed on August 16, 2022, and the program remained in force during Balint’s House term, including surviving a Supreme Court challenge on May 18, 2026. But Balint took office on January 3, 2023, after the key restriction-lifting law had already passed, so she does not merit full delivery credit for the underlying outcome. The evidence shows she was engaged on health-care and medication-affordability issues during her term, which supports some credit for alignment and ongoing support, but not enough candidate-specific contribution to count as fully delivered by her.

provider codex_cli · model gpt-5.4 · confidence 86%